The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a huge mover today! About 681,148 shares traded hands. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 376.92% since April 18, 2016 and is uptrending. It has outperformed by 372.49% the S&P500.
The move comes after 9 months positive chart setup for the $61.55 million company. It was reported on Nov, 18 by Barchart.com. We have $3.48 PT which if reached, will make NASDAQ:EBIO worth $22.16M more.
Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage
Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Eleven Biotherapeutics has been the topic of 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc. The rating was downgraded by Citigroup to “Neutral” on Tuesday, January 19. The company was maintained on Wednesday, March 16 by Citigroup. Leerink Swann maintained the stock with “Outperform” rating in Saturday, August 15 report. Leerink Swann downgraded Eleven Biotherapeutics Inc (NASDAQ:EBIO) on Tuesday, January 19 to “Market Perform” rating.
According to Zacks Investment Research, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.”
Insitutional Activity: The institutional sentiment increased to 2.29 in 2016 Q2. Its up 1.29, from 1 in 2016Q1. The ratio increased, as 5 funds sold all Eleven Biotherapeutics Inc shares owned while 4 reduced positions. 5 funds bought stakes while 4 increased positions. They now own 2.51 million shares or 36.45% more from 1.84 million shares in 2016Q1.
Citigroup holds 600 shares or 0% of its portfolio. Royal Bancorporation Of Canada last reported 500 shares in the company. Moreover, Two Sigma Secs Ltd Liability Com has 0.02% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 25,428 shares. Susquehanna Grp Llp accumulated 0% or 26,654 shares. Blackrock Fund Advsr has invested 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Blackrock Institutional Na has 149,618 shares for 0% of their US portfolio. Fiduciary Co holds 0% or 10,000 shares in its portfolio. Flagship Ventures 2007 General Partner Limited Liability holds 1.91 million shares or 2.98% of its portfolio. The Pennsylvania-based Vanguard Group has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Retail Bank Of Ny Mellon holds 0% or 67,483 shares in its portfolio. Moreover, Morgan Stanley has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 1,503 shares. The Illinois-based Grp Inc One Trading Limited Partnership has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Guggenheim Cap Lc has 0% invested in the company for 10,331 shares. Renaissance Tech Limited Co reported 118,500 shares or 0% of all its holdings. Bank Of Montreal Can holds 0% or 15,000 shares in its portfolio.
EBIO Company Profile
Eleven Biotherapeutics, Inc., incorporated on February 25, 2008, is a preclinical-stage biopharmaceutical company. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.